Gilead Sciences, a biopharmaceutical company, completed the acquisition of CymaBay Therapeutics, a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases, for $4.3bn. “The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis. I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet need. We look forward to advancing seladelpar and building on Gilead’s more than 20-year legacy of treating and curing liver disease on a global scale,” Daniel O’Day, Gilead Sciences Chairman and CEO.